Preclinical News and Research

RSS

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

International researchers to assess role of pre-clinical animal models in drug discovery

The New York Academy of Sciences and the Global Medical Excellence Cluster (GMEC), in collaboration with Imperial College London and King's College London, will host a two-day scientific conference, "Animal Models and Their Value in Predicting Drug Efficacy and Toxicity," that will provide a forum to critically examine the role of pre-clinical animal models in drug discovery.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

Researchers use ultrasound to improve quality of blood stem cell transplant

Transplantation of haematopoietic stem cells is an effective treatment for patients with malignant blood diseases. The composition and quality of the transplanted cells are crucial to the outcome. Researchers from Lund University, Sweden, have now developed a method to improve the quality of the transplanted cells using ultrasound for cell separation.

7 Sep 2011

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Discovery Labs, Inc. today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN(lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

6 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Using a strategy based on treating cancer cells that carry a specific genetic signature - hyper-expression of the protein Myc - with therapy that affects the stability of the cell's DNA, more effective results can be achieved.

5 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Key international experts to attend major European bone congress in Bourse, France

Key international experts in the bone field are to be featured speakers and session leaders at the upcoming European Congress on Osteoporosis & Osteoarthritis (IOF-ECCEO12). As the major European bone event of the year, IOF-ECCEO12 will present the latest research and clinical advances in the bone field.

3 Sep 2011

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

Researchers from the Mayo Clinic and representatives from IC-MedTech signed a collaborative research agreement with Summa Health System to study the usage of Apatone, a proprietary combination of Vitamin-C and Vitamin-K3.

2 Sep 2011

UTHealth Phase I trial: Bone marrow stem cell therapy feasible, safe for acute stroke patients

Using a patient's own bone marrow stem cells to treat acute stroke is feasible and safe, according to the results of a ground-breaking Phase I trial at The University of Texas Health Science Center at Houston.

2 Sep 2011

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.

31 Aug 2011

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.

31 Aug 2011

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

Preclinical News and Research

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

International researchers to assess role of pre-clinical animal models in drug discovery

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

Researchers use ultrasound to improve quality of blood stem cell transplant

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Amakem receives €18m in Series A round of funding

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Key international experts to attend major European bone congress in Bourse, France

Mayo Clinic and IC-MedTech enter collaborative research agreement with Summa Health System

UTHealth Phase I trial: Bone marrow stem cell therapy feasible, safe for acute stroke patients

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

BioLineRx second quarter net loss decreases to NIS 16.4 million

KalVista raises £8 million in series A round of funding

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics